Torrent Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2026. For the fourth quarter, the company reported sales was INR 41,280 million compared to INR 29,090 million a year ago. Revenue was INR 41,800 million compared to INR 29,410 million a year ago. Net income was INR 3,890 million compared to INR 4,980 million a year ago. Basic earnings per share from continuing operations was INR 11.51 compared to INR 14.71 a year ago. Diluted earnings per share from continuing operations was INR 11.51 compared to INR 14.71 a year ago.
For the full year, sales was INR 137,530 million compared to INR 113,170 million a year ago. Revenue was INR 138,860 million compared to INR 115,390 million a year ago. Net income was INR 21,630 million compared to INR 19,110 million a year ago. Basic earnings per share from continuing operations was INR 63.92 compared to INR 56.47 a year ago. Diluted earnings per share from continuing operations was INR 63.92 compared to INR 56.47 a year ago.
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
